
Cytokinetics, Incorporated CYTK
$ 63.82
0.65%
Quarterly report 2025-Q3
added 11-05-2025
Cytokinetics, Incorporated DSO Ratio 2011-2026 | CYTK
Annual DSO Ratio Cytokinetics, Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 177 | 34.7 | 100 | 146 | 31.3 | 70.1 | 78.6 | 30.4 | 0.0823 | 0.153 | 363 | 0.0595 | 0.193 | 1.28 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 363 | 0.0595 | 73.8 |
Quarterly DSO Ratio Cytokinetics, Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 241 | 7.12 | 65.2 | - | - | - | 421 | 105 | 11.4 | - | 41.6 | 3.11 | 2.3 K | - | 28.1 | 116 | 62.2 | - | 9.67 | 112 | 114 | - | 77.8 | 66 | 39.9 | - | 19.1 | 32.8 | 28.9 | -5.64 K | 16.4 | 33.2 | 12.5 | 0.07 | 0.04 | 0.19 | 1.08 | 0.94 | - | - | 1.13 | 0.23 | - | - | 1.23 | 0.4 | - | - | 10.4 | 3.91 | - | - | 5.16 | 12.4 | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.3 K | -5.64 K | -43.1 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
Adagene
ADAG
|
53.8 | $ 2.4 | -3.61 % | $ 135 M | ||
|
Aptorum Group Limited
APM
|
20.6 | $ 0.97 | 0.81 % | $ 5.29 M | ||
|
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.62 | 1.91 % | $ 8.71 B | ||
|
Biogen
BIIB
|
57.9 | $ 172.5 | 0.53 % | $ 25.1 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Catalyst Biosciences
CBIO
|
3.24 | $ 12.1 | -5.47 % | $ 797 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Cellectis S.A.
CLLS
|
94.5 | $ 4.16 | -5.88 % | $ 116 M | ||
|
BioXcel Therapeutics
BTAI
|
16.3 | $ 1.79 | -1.92 % | $ 4.54 M | ||
|
Ascendis Pharma A/S
ASND
|
132 | $ 231.73 | -1.55 % | $ 5 B | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 67.09 | 0.06 % | $ 8.97 B | ||
|
Compugen Ltd.
CGEN
|
60.8 | $ 2.05 | -2.15 % | $ 184 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 4.41 | -1.34 % | $ 9.6 B | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 26.4 | 1.85 % | $ 1.28 B | ||
|
Coherus BioSciences
CHRS
|
263 | $ 2.27 | 10.19 % | $ 214 M | ||
|
Amneal Pharmaceuticals
AMRX
|
55.7 | $ 13.54 | 1.12 % | $ 4.18 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | ||
|
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Celldex Therapeutics
CLDX
|
86.5 | $ 26.48 | 2.16 % | $ 1.71 M | ||
|
Aytu BioScience
AYTU
|
150 | $ 2.73 | 1.11 % | $ 17.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B |